无创通气与经鼻高流量氧疗用于ICU拔管后呼吸衰竭:一项随机临床试验的事后分析
该研究为多中心随机对照试验的事后分析,纳入拔管后7天内发生呼吸衰竭的ICU患者146例,根据呼吸衰竭发生后采用的氧疗策略分为无创通气交替经鼻高流量氧疗组(84例)与单用经鼻高流量氧疗组(62例)。主要终点28天死亡率分别为18%(15/84)与29%(18/62),差异-11%(95%CI -25至2),p=0.12,未达统计学显著。在呼吸衰竭发生时合并高碳酸血症的46例患者中,28天死亡率无创通气组3%(1/33) vs 单用高流量组31%(4/13),差异-28%(95%CI -54至-6),p=0.006。拔管后呼吸衰竭发生后48小时内再插管比例分别为44%(37/84)与52%(32/62),p=0.21。作者认为无创通气交替经鼻高流量氧疗可能不增加死亡风险。
要点
- 拔管后呼吸衰竭患者28天死亡率:无创通气交替经鼻高流量氧疗18%(15/84) vs 单用经鼻高流量氧疗29%(18/62),差异-11%(95%CI -25至2),p=0.12,未达统计学显著。
- 合并高碳酸血症的拔管后呼吸衰竭患者28天死亡率:无创通气组3%(1/33) vs 单用高流量组31%(4/13),差异-28%(95%CI -54至-6),p=0.006。
- 拔管后呼吸衰竭发生后48小时内再插管比例:无创通气组44%(37/84) vs 单用高流量组52%(32/62),p=0.21。
- 651例拔管患者中158例(25%)发生呼吸衰竭,146例纳入分析;拔管后1小时内再插管及未接受治疗即再插管者被排除。
- 作者认为拔管后呼吸衰竭患者使用无创通气交替经鼻高流量氧疗可能不增加死亡风险。
适用人群与场景
- ICU拔管后7天内发生呼吸衰竭的患者。
- 排除拔管后1小时内再插管者及未接受治疗即再插管者。
研究设计与关键结果
- 研究类型:多中心随机对照试验的事后分析;651例拔管患者中158例(25%)发生呼吸衰竭,146例纳入分析。
- 分组:根据拔管后呼吸衰竭发生后采用的氧疗策略分为无创通气交替经鼻高流量氧疗组(84例)与单用经鼻高流量氧疗组(62例)。
- 主要终点28天死亡率:无创通气组18%(15/84) vs 单用高流量组29%(18/62),差异-11%(95%CI -25至2),p=0.12。
- 高碳酸血症亚组(46例)28天死亡率:无创通气组3%(1/33) vs 单用高流量组31%(4/13),差异-28%(95%CI -54至-6),p=0.006。
- 呼吸衰竭发生后48小时内再插管比例:无创通气组44%(37/84) vs 单用高流量组52%(32/62),p=0.21。
证据类型、等级与局限
- 证据类型:多中心随机对照试验的事后分析。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,拔管后呼吸衰竭患者使用无创通气交替经鼻高流量氧疗可能不增加死亡风险。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: In intensive care units (ICUs), patients experiencing post-extubation respiratory failure have poor outcomes. The use of noninvasive ventilation (NIV) to treat post-extubation respiratory failure may increase the risk of death. This study aims at comparing mortality between patients treated with NIV alternating with high-flow nasal oxygen or high-flow nasal oxygen alone.
METHODS: Post-hoc analysis of a multicenter, randomized, controlled trial focusing on patients who experienced post-extubation respiratory failure within the 7 days following extubation. Patients were classified in the NIV group or the high-flow nasal oxygen group according to oxygenation strategy used after the onset of post-extubation respiratory failure. Patients reintubated within the first hour after extubation and those promptly reintubated without prior treatment were excluded. The primary outcome was mortality at day 28 after the onset of post-extubation respiratory failure.
RESULTS: Among 651 extubated patients, 158 (25%) experienced respiratory failure and 146 were included in the analysis. Mortality at day 28 was 18% (15/84) using NIV alternating with high-flow nasal oxygen and 29% (18/62) with high flow nasal oxygen alone (difference, - 11% [95% CI, - 25 to 2]; p = 0.12). Among the 46 patients with hypercapnia at the onset of respiratory failure, mortality at day 28 was 3% (1/33) with NIV and 31% (4/13) with high-flow nasal oxygen alone (difference, - 28% [95% CI, - 54 to - 6]; p = 0.006). The proportion of patients reintubated 48 h after the onset of post-extubation respiratory failure was 44% (37/84) with NIV and 52% (32/62) with high-flow nasal oxygen alone (p = 0.21).
CONCLUSIONS: In patients with post-extubation respiratory failure, NIV alternating with high-flow nasal oxygen might not increase the risk of death. Trial registration number The trial was registered at http://www.clinicaltrials.gov with the registration number NCT03121482 the 20th April 2017.
参考来源
- Thille AW, Monseau G, Coudroy R, et al. Non-invasive ventilation versus high-flow nasal oxygen for postextubation respiratory failure in ICU: a post-hoc analysis of a randomized clinical trial. Crit Care. 2021. PMID: 34183053. doi:10.1186/s13054-021-03621-6
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。